Identification of oncogenic BRAF mutations in primary and metastatic melanomas supports a linear model of clonal evolution in cancer. Some mutational studies, however, have failed to identify BRAF mutations in metastatic tumors from patients with BRAFmutant primary melanomas. Using a combination of methods, Riveiro-Falkenbach et al. (2015) assert that technical issues, and not clonal heterogeneity, may explain prior discordant mutational results
Purpose. ...
Purpose. ...
International audienceBACKGROUND:BRAF mutations are present in 40% of human skin melanomas. Mutated ...
The rationale for using small molecule inhibitors of oncogenic proteins as cancer therapies depends,...
The rationale for using small molecule inhibitors of oncogenic proteins as cancer therapies depends,...
Mutation landscape in melanoma patients clinical implications of heterogeneity o
To determine if BRAF V600E is conserved during melanoma disease progression and the effect of hetero...
Abstract: Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the development...
Background: BRAF mutation frequencies in melanoma subtypes have clinical implications and offer pa...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600-mutant m...
The era of targeted therapy has introduced a new therapeutic perspective for melanoma patients. Trea...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF(V600)-mutant ...
Purpose. ...
WOS: 000369490000004PubMed ID: 26630683Background:The BRAF-V600 mutation is the most common mutation...
Purpose. ...
Purpose. ...
Purpose. ...
International audienceBACKGROUND:BRAF mutations are present in 40% of human skin melanomas. Mutated ...
The rationale for using small molecule inhibitors of oncogenic proteins as cancer therapies depends,...
The rationale for using small molecule inhibitors of oncogenic proteins as cancer therapies depends,...
Mutation landscape in melanoma patients clinical implications of heterogeneity o
To determine if BRAF V600E is conserved during melanoma disease progression and the effect of hetero...
Abstract: Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the development...
Background: BRAF mutation frequencies in melanoma subtypes have clinical implications and offer pa...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600-mutant m...
The era of targeted therapy has introduced a new therapeutic perspective for melanoma patients. Trea...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF(V600)-mutant ...
Purpose. ...
WOS: 000369490000004PubMed ID: 26630683Background:The BRAF-V600 mutation is the most common mutation...
Purpose. ...
Purpose. ...
Purpose. ...
International audienceBACKGROUND:BRAF mutations are present in 40% of human skin melanomas. Mutated ...